

ACETYLENIC CHOLESTERYL DERIVATIVES AS IRREVERSIBLE
INHIBITORS OF ECDYSONE BIOSYNTHESIS.

Alain Burger¹, Françoise Colobert², Charles Hetru² and Bang Luu¹.

¹UA CNRS 31, Laboratoire de Chimie Organique des Substances Naturelles,
Université Louis Pasteur, 5 rue Blaise Pascal, 67000 Strasbourg, France; ²UA
CNRS 672, Laboratoire de Biologie Générale, Université Louis Pasteur, 12 rue de
l'Université, 67000 Strasbourg, France.

(Received in Belgium 16 November 1987)

Abstract. - Two series of acetylenic derivatives of cholesterol were synthesized from stigmasterol and pregnenolone. These compounds carry an acetylenic function at C-22 and were devised with the aim to inhibit the C-22 hydroxylation of ecdysone biosynthesis by a suicide-substrate mechanism. Two of these compounds (15a, 15f) inhibit the synthesis of ecdysone in follicular cells under *in vitro* conditions. The inhibition is selective of the C-22 hydroxylase system.

Arthropods occupy most ecological niches in the environment. They are believed to represent more than 90% of the species of the animal kingdom. A major characteristic of their development is the process of regular shedding of the old cuticle and synthesis of a new cuticle. This process, known as molt, is controlled by the steroid hormone ecdysone (4) (Gk. ecdysis = molt). Ecdysone is synthesized during postembryonic development (and possibly during the late stages of embryogenesis) in endocrine glands referred to as "prothoracic glands" in insects and "Y organs" in crustaceans. Reproductively competent female insects also synthesize ecdysone in their ovaries ^{1,2}.

In addition to triggering the cycles of cuticulogenesis, ecdysone is involved in the control of a variety of developmental and reproductive processes, although our information is still fragmentary in this respect ³. In order to get a better understanding of the functions of ecdysone, and keeping in mind possible practical applications, we have set up a program for the syntheses of selective inhibitors of ecdysone biosynthesis. Suicide substrate inhibitors seemed to be suitable for these studies because of their specific and irreversible action. A suicide substrate is a molecule homologous to the natural substrate of an enzyme and capable of binding irreversibly to this enzyme as a consequence of the enzymatic changes ⁴⁻⁶; whereby the catalytic activity of the enzyme is destroyed.

Cholesterol is known to be the first C₂₇ precursor in the biosynthesis of ecdysone, but until now only the last steps of the pathway of this biosynthesis have been well established. They consist of a sequence of hydroxylations at C-25, C-22 and finally at C-2 ^{7,8}.

As a first approach, we have chosen to synthesize compounds which are able to inhibit irreversibly the hydroxylation at C-22. Recent results have indicated that the enzyme responsible for the C-22 hydroxylation is a cytochrome P-450 dependent monooxygenase⁹. The acetylenic function is known to induce inactivation of this type of enzymes ^{10,11}.




Figure 1 : Ecdysone biosynthesis.

From the chemical standpoint, excellent information is available on the side-chain of steroids ^{12,13}. We have undertaken the syntheses of sterols having the nucleus of cholesterol and bearing a side chain with a triple bond at C-22. We expected molecules structurally similar to cholesterol to enter more easily the biosynthetic tissue.

In this paper, we describe the syntheses of two series of cholesteryl derivatives and we present several biological results.

CHEMICAL RESULTS.

The syntheses of compounds 8 and 11 were achieved as shown in scheme A. The dichlorovinyl derivative 5 was prepared from stigmasterol, without epimerization at C-20, according to Salmond *et al.*¹⁴. Treatment with butyllithium converted 5 to the lithium acetylide 6, the common intermediate.

7(a-d) were obtained quantitatively from 6 by hydrolysis or by alkylations (table A). Alkylation of 6, except in the case of 7b with methyl iodide, was too sluggish in pure THF. This problem was solved by using hexamethylphosphotriamide ^{15,16}.


Reaction of 6 with *i*-butyl bromide gave 2 products. The expected 7e was obtained only in 33% yield, the major reaction, with elimination of HBr in the electrophile ¹⁷, furnished 7a (67%). However, the yield of 7e has been improved up to 58% by using the following sequence of operations: after the initial alkylation, 6 was regenerated *in situ* with another equivalent of BuLi and subsequently alkylated with *i*-butyl bromide to yield 7e.

Condensation of 6 with an epoxide, 2-methyl-propan-1,2-oxide, as described in Salmond's procedure ¹⁴, gave a mixture of products. An alternative route was explored (scheme A): methyl iodide was added to 6 to form 7b, which was directly converted to the propargylanion 9 by BuLi ^{18,19}. The ambident anion 9 was treated with acetone to form regioselectively 10 (88%). This one-pot procedure furnished 10 with a better yield than that reported earlier ¹⁴.

Acid catalysed hydrolyses of the *i*-methyl ethers 7 and 10 completed subsequently the syntheses of 8 and 11 (84 to 95%).

The acetylenic derivatives of type 15 were synthesized stereospecifically as shown in scheme B. Their precursors 14 were obtained by reacting the

SCHEME A.



a, R=H; b, R=Me; c, R=Et, d, R=Pr
e, R=i-Bu.

i) 2 BuLi, j) R-X, k) p-TsOH cat., l) MeI, m) Acetone

Table A.


Compounds	Electrophiles	Conversion in %
7a	H ₂ O	quant.
7b	MeI	quant.
7c	EtBr	quant.
7d	PrBr	quant.
7e	i-BuBr	33
10	acetone	88

corresponding lithium acetylide (3 eq) with the protected pregnenolone **13** ^{20,21} (Table B). Addition of **13** to the lithiated dianion **22** of carbinol **16** ²³ furnished **14f** (53%) and the starting material **13** (37%). *In situ* generation of the trimethylsilyl ether of **16**, followed by treatment with methyl lithium and **13** gave **14f** in 92% yield after acid hydrolysis and purification.

The nucleophilic attack of the lithium acetylide on **13** was stereospecific ¹², giving the (20R) stereoisomer with only a trace of the more polar isomer (TLC, NMR). The (20R) and (20S) isomers have quite distinct NMR spectra: C-18 methyl protons appear at about 0.98 ppm in the case of (20R) and at about 0.89 ppm in the case of (20S) isomer.

Fluoride ions (Bu₄NF) removed quantitatively the t-butyl-dimethylsilyl ether moiety in **14**, to yield **15** (96 to 98%).

SCHEME B.



i) TBDMSCl, (i-Pr)₂NEt; j) LiC≡CR, -78°C; k) Bu₄NF

Table B.

Compounds <u>14</u>	R	Isolated yield in %
<u>a</u>	SiMe ₃	93
<u>b</u>	Me	92
<u>c</u>	Et	94
<u>d</u>	Pr	92
<u>e</u>	i-Bu	96
<u>f</u>	CH ₂ C(CH ₃) ₂ OH	92

(15 has respectively the same R as 14 except 15a, R=H)

BIOLOGICAL RESULTS.

All the biological tests were performed on the migratory locust, *Locusta migratoria*. In this insect, ecdysone is produced in the prothoracic glands during postembryonic development and in the follicular cells of the ovaries of adult vitellogenic females ²⁴.

The molecules, which we have synthesized (8, 11, 15), have been tested *in vitro* on the prothoracic glands of the larvae. Three of these compounds (8a, 15a, 15f) induce a decrease in the synthesis of ecdysone. The depressory effect on the biosynthesis was 30% in the presence of 8a and of 60% in the presence of 15a and 15f, at a concentration of 10⁻⁴M, and it was dose-dependent. The inhibition of synthesis of ecdysone by these three inhibitors was not suppressed by rinsing the glands, followed by re-incubation in a fresh medium in the absence of inhibitor; the effect was therefore most probably irreversible. Concomitant addition of each of 15a and 15f and tritiated ecdysone precursors

with prothoracic glands indicated that these compounds inhibited selectively the C-22 hydroxylase system. The details of these biological results are described in another publication 25.

In the present paper, we shall focus on the activity of 15a and 15f on ecdysone biosynthesis in the follicular cells of the adult female. To appreciate the inhibitory capacity of these molecules, we have studied their influence on the conversion of a labelled precursor of ecdysone, 2,22-dideoxyecdysone 2 26, in the follicular cells.

Ovaries were excised from adult vitellogenic females and the oocytes (60-100) were divided into three equivalent batches which were separately incubated with equal quantities of labelled 2,22-dideoxyecdysone. In addition, to one batch we added 15a, and to a second 15f, the third serving as a control. The labelled metabolites of the three incubations were extracted, separated by HPLC and identified by co-elution with reference substances as ecdysone (4), 2-deoxyecdysone (3) and 22-deoxyecdysone.

Table C presents the conversion rates observed during the incubations. In comparison to the control, there is a 30% decrease in the conversion of precursor 2 to ecdysone in the presence of 15a and of 66% in the presence of 15f. Hence these two molecules have an inhibitory effect on the biosynthesis of ecdysone in the follicular cells in vitro. The level of conversion of 2 to 22-deoxyecdysone is similar in all three cases. The C-2 hydroxylation is therefore not affected. In comparison to the control, there is a 42% decrease in the conversion of 2 to 2-deoxyecdysone in the presence of 15a and of 78% in the presence of 15f. The C-22 hydroxylation system is strongly depressed. These results indicate that 15a and 15f inhibit the C-22 hydroxylation during ecdysone biosynthesis in the follicular cells.

Conversion products %	Unconverted 2,22-dideoxyecdysone (<u>2</u>)	22-Deoxyecdysone	2-Deoxyecdysone (<u>3</u>)	Ecdysone (<u>4</u>)
Control	54	7.5	5.9	3.6
Inhibitor <u>15a</u>	61	7.6	3.4	2.5
Inhibitor <u>15f</u>	67	7.8	1.3	1.2

Table C.

The oocytes of five vitellogenic females (when the ecdysteroids synthesis is maximum) were dissected and divided equally in three tubes. Each tube contained 1 ml of Landureau's medium and 270 kBq of tritiated 2,22-dideoxyecdysone (2) (specific activity 22 TBq/mmol). The first tube was the control. In the two others, 15a and 15f were added to react at a final concentration of 10^{-4} M. After 16 h of incubation, the labelled ecdysteroids were extracted and separated by reversed phase HPLC on a C-18 column and identified by co-elution with reference substances. The radioactivity of each labelled metabolite was measured by scintillation counting. The rate of conversion in each metabolite was calculated in comparison with the total of labelling and expressed in percentage. In this table we have not taken into account the minor unidentified conversion products.

CONCLUSION.

The reduction of the concentration of circulating ecdysteroids in insects is a challenge which has been taken up by many authors ²⁷. The techniques adopted aim at suppressing the first precursor of ecdysone biosynthesis, i.e. cholesterol. Insects are unable to synthesize *de novo* cholesterol which they take up from the diet, except for phytophagous insects, which rely on dealkylation of phytosterols for their cholesterol supply. Prestwich and coll. ^{28,29} and Ikekawa and coll. ³⁰ have developed inhibitors of the dealkylation process of phytosterols. An indirect approach has been used by Costet *et al.* ³¹. Plants treated with a systemic fungicide of the morpholin family replace their Δ^5 sterols to a large extent by cyclopropylsterols and Δ^8 sterols as a result of the selective inhibition of two enzymes of the biosynthetic pathway of plant sterols. When reared on experimental plants, insects were shown to be unable to produce normal levels of ecdysone, as a direct result of the deficiencies of Δ^5 sterols in their diet.

These approaches used to lower the normal levels of cholesterol have some limitations when the biological roles of ecdysone are to be investigated. Indeed, as cholesterol is an essential constituent of eukaryotic membranes, its depletion can affect non-specific processes unrelated to any hormonal control by ecdysone. These drawbacks could be overcome by the synthesis of specific inhibitors of the last stages of ecdysone biosynthesis. Several of the molecules which we have now synthesized are of potential interest as they selectively and irreversibly inhibit C-22 hydroxylation. We are developing our efforts to synthesize related compounds effective on this and other enzymes of ecdysone biosynthesis, at lower concentrations. In particular we will synthesize compounds having the ecdysone ring system (instead of the bare cholesterol ring system as in the present paper), and bearing an acetylenic group at C-22.

EXPERIMENTAL.

Melting points were measured on a Reichert microscope and are uncorrected. (α)D were measured on a Perkin-Elmer 141 polarimeter in CHCl_3 . IR spectra were recorded in KBr on a Perkin-Elmer spectrometer and a Pye Unicam SP3-300S infrared spectrophotometer Philips. Absorptions are given in cm^{-1} . NMR spectra were recorded on a Bruker SY (200MHz) apparatus with CHCl_3 (7.27 ppm) or CH_2Cl_2 (5.35 ppm) as internal standard for ^1H NMR and CDCl_3 (76.9 ppm) or CD_2Cl_2 (53.6 ppm) as internal standard for ^{13}C NMR. The chemical shifts are reported in ppm downfield from TMS. MS were measured on a Thomson THN 208 and a LKB 9000S apparatus by direct introduction using an ionization potential of 70 eV. Microanalyses were performed by the Strasbourg Division of the Service Central de Microanalyses of the CNRS. GLC analysis were carried out on a Girdel Chromatograph 300 fitted with a flame ionization detector. A packed glass column (OV1, 3%) (210 cm x 0.2 cm) was used. TLC were run on pre-coated plates of silica gel 60F254 (Merck) and silica gel (40 - 63 μm , Merck) was used for column chromatography.

Conversions given in the table A were determined employing the following conditions of GLC: injector and detector temperatures were respectively 200 and 300°C, GLC was run from 200 to 290°C (5°C/min) with a flow of 25 ml/min (He).

General procedure for the preparation of lithium acetylide (6).

BuLi in hexane (2.2 eq, 820 μl , 1.2 mmol.) was added dropwise to a stirred solution (-78°C) of the dichlorovinylpregnane ¹⁴ (5) (230 mg, 0.56 mmol.) in dry THF (20 ml) under argon. Stirring was continued for 1h at -78°C and another 2h at R.T. This solution was used for alkylation.

6 β -Methoxy-3 α ,5-cyclo-24-nor-5 α -chol-22-yne (7a).

Aqueous NaCl was added to the solution of lithium acetylide 6 in THF (0.56 mmol., 20 ml). The mixture was extracted with ether, washed with 6N HCl , water,

then dried on Na_2SO_4 , filtered over silica gel and evaporated to give **7a** (190mg, quant.).

mp = 74-76°C (lit. ¹⁴, 74-76°C). (α)_D = +54° (c = 0.8). IR: 3320 (m), 3080 (w), 2110 (w), 1110 (s). ¹H NMR (CDCl_3): 0.43 (1H, dd: J₁ = 8 Hz and J₂ = 5 Hz, H-4), 0.65 (1H, t: J = 5 Hz, H-4), 0.74 (3H, s, H-18), 1.02 (3H, s, H-19), 1.22 (3H, d: J = 7 Hz, H-21), 2.01 (1H, d: J = 2.5 Hz, H-23), 2.43 (1H, m: w_{1/2} = 20 Hz, H-20), 2.77 (1H, m: w_{1/2} = 6.5 Hz, H-6), 3.32 (3H, s, MeO). ¹³C NMR in table 1. MS m/e: 340 (M⁺, 100), 325 (44), 308 (50), 285 (54), 255 (31).

General Procedure for the deprotection of the i-ether group.

A solution of **7** (56 mmol.) and p-TsOH acid (catalytic amount) in dioxan/water (20 ml, 7/3) was stirred at 80°C for 3h, and then poured into an aqueous solution of NaCl. Extraction with ether, and chromatography over silica gel (toluen-AcOEt, 5%) gave **8**.

24-Nor chol-5-en-22-yn-3 β -ol (8a).

7a (190 mg) was hydrolysed according to the general procedure to give **8a** (163mg, 89%).

mp = 145-146°C (EtOH). (α)_D = -50° (c = 3.5). IR: 3620 (m), 3490 (bm), 3280 (s), 3260 (s), 3040 (w), 1670 (w), 1070 (m). ¹H NMR (CDCl_3): 0.71 (3H, s, H-18), 1.01 (3H, s, H-19), 1.23 (3H, d: J = 7 Hz, H-21), 2.03 (1H, d: J = 2 Hz, H-23), 2.48 (1H, m: w_{1/2} = 18 Hz, H-20), 3.54 (1H, m: w_{1/2} = 25 Hz, H-3), 5.35 (1H, d: J = 5 Hz, H-6). ¹³C NMR in table 1. MS m/e: 326 (M⁺, 100), 311 (13), 308 (29), 293 (12), 273 (15), 255 (11), 241 (19), 215 (12). Found: C, 84.65; H, 10.58. Calc for $\text{C}_{23}\text{H}_{34}\text{O}$ (326.5): C, 84.60; H, 10.50.

Chol-5-en-22-yn-3 β -ol (8b) from 6.

MeI (75 μ l, 12 mmol.) was added dropwise to a stirred and cooled solution (-10°C) of lithium acetylide **6** in dry THF (20 ml, 0.56 mmol.) under argon. After stirring for 3h at R.T. the usual work-up gave the crude product **7b** and after hydrolysis, according to the general procedure, **8b** was obtained (172 mg, 90%).

mp = 104-105°C (methanol). (α)_D = -46° (c = 2.8). IR: 3540 (bs), 3040 (w), 1670 (w), 1070 (m). ¹H NMR (CDCl_3): 0.69 (3H, s, H-18), 1.01 (3H, s, H-19), 1.17 (3H, d: J = 7 Hz, H-21), 1.77 (3H, d: J = 2 Hz, H-24), 2.39 (1H, m: w_{1/2} = 20 Hz, H-20), 3.55 (1H, m: w_{1/2} = 25 Hz, H-3), 5.36 (1H, d: J = 5 Hz, H-6). ¹³C NMR in table 1. MS m/e: 340 (M⁺, 100), 325 (14), 322 (17), 307 (14), 273 (20), 255 (35), 229 (17). Found: C, 82.28; H, 10.79. Calc. for $\text{C}_{24}\text{H}_{36}\text{O}$, 0.5 H_2O (349.54): C, 82.46; H, 10.67.

26,27-Dinor cholest-5-en-22-yn-3 β -ol (8c) from 6.

EtBr (126 μ l, 1.7 mmol.) and dry HMPA (2 ml) were added dropwise to a stirred and cooled solution (-10°C) of lithium acetylide **6** in dry THF (0.56 mmol., 20 ml). After stirring for 1.5 h at R.T., **8c** was isolated in the similar way as described for **8b** (178 mg, 90%).

mp = 112-113°C (acetone). (α)_D = -44° (c = 0.9). IR: 3440 (bm), 3040 (w), 1670 (w), 1060 (s). ¹H NMR (CDCl_3): 0.70 (3H, s, H-18), 1.01 (3H, s, H-19), 1.10 (3H, t: J = 7.5 Hz, H-25), 1.17 (3H, d: J = 7 Hz, H-21), 2.34 (2H, qd: J₁ = 7.5 Hz and J₂ = 2 Hz, H-24), 2.42 (1H, m: w_{1/2} = 20 Hz, H-20), 3.55 (1H, m: w_{1/2} = 25 Hz, H-3), 5.35 (1H, d: J = 5 Hz, H-6). ¹³C NMR in table 1. MS m/e: 354 (M⁺, 100), 339 (16), 336 (18), 321 (12), 273 (21), 269 (14), 255 (32), 243 (21). Found: C, 84.80; H, 11.08. Calc. for $\text{C}_{25}\text{H}_{38}\text{O}$ (354.6): C, 84.69; H, 10.80.

27-Nor cholest-5-en-22-yn-3 β -ol (8d) from 6.

8d (173 mg, 84%) was prepared in the same manner as described for the synthesis of **8b**, using PrBr (155 μ l, 1.7 mmol.), dry HMPA (2 ml) and lithium acetylide **6** in THF (0.56 mmol., 20 ml).

mp = 107-108°C and 114-115°C (MeOH). (α)_D = -43° (c = 1.3). IR: 3440 (bm), 3040 (w), 1670 (w), 1070 (s). ¹H NMR (CDCl_3): 0.69 (3H, s, H-18), 0.96 (3H, t: J = 7.5 Hz, H-26), 1.00 (3H, s, H-19), 1.17 (3H, d: J = 7 Hz, H-21), 2.11 (2H, td: J₁ = 7 Hz and J₂ = 2 Hz, H-24), 2.43 (1H, m: w_{1/2} = 20 Hz, H-20), 3.52 (1H, m: w_{1/2} = 25 Hz, H-3), 5.35 (1H, d: J = 5 Hz, H-6). ¹³C NMR in table 1. MS m/e: 368 (M⁺, 100), 353 (12), 350 (18), 335 (13), 283 (15), 273 (19), 257 (23), 255 (28). Found: C, 84.83; H, 11.10. Calc. for $\text{C}_{26}\text{H}_{40}\text{O}$ (368.58): C, 84.71; H, 10.94.

Cholest-5-en-22-yn-3 β -ol (8e) from 6.

i-BuBr (130 μ l, 1.2 mmol.) and dry HMPA (2 ml) were added dropwise to a stirred and cooled solution (-10°C) of lithium acetylide **6** in dry THF (0.56 mmol., 20 ml) under Ar. After 5h at R.T., the solution was cooled again at -78°C and BuLi in hexane (1.2 ml, 1.2 mmol.) was introduced dropwise. The reaction temperature was raised to -10°C during 25 min and another quantity of i-BuBr (130 μ l, 1.2 mmol.) was introduced dropwise. The stirring was continued for further 3h at R.T. Usual work-up and chromatography over silica gel

(hexane-Et₂O 2%) gave **7e**, which was hydrolysed to yield **8e** (94 mg, 44%). mp = 110–111°C (methanol). (α)_D = -40° (c = 0.8). IR: 3420 (bm), 3040 (w), 1670 (w), 1070 (s). ¹H NMR (CDCl₃): 0.70 (3H, s, H-18), 0.95 (6H, d : J = 6.5 Hz, H-26 and H-27), 1.01 (3H, s, H-19), 1.18 (3H, d : J = 7 Hz, H-21), 2.03 (2H, dd : J₁ = 6.5 Hz and J₂ = 2 Hz, H-24), 2.44 (1H, m : w_{1/2} = 20 Hz, H-20), 3.55 (1H, m : w_{1/2} = 25 Hz, H-3), 5.35 (1H, d : J = 5 Hz, H-6). ¹³C NMR in table 1. MS m/e: 382 (M⁺, 100), 367 (11), 364 (14), 349 (7), 297 (10), 273 (18), 271 (14), 255 (17). Found: C, 82.91; H, 11.33. Calc. for C₂₇H₄₂O, 0.5 H₂O (391.61): C, 82.80; H, 11.07.

Cholest-5-en-22-yn-3 β ,25-diol (11) from 6.

MeI (30 μ l, 0.48 mmol.) was added dropwise to a stirred and cooled solution (-10°C) of lithium acetylide **6** in dry THF (0.37 mmol, 10 ml). After stirring for 3h at R.T., the solution was cooled to 0°C and BuLi in hexane (650 μ l, 0.91 mmol.) was introduced dropwise. The stirring was continued for 2 h at 0°C, and then the solution was further cooled to -78°C and anhydrous acetone (110 μ l, 1.48 mmol.) was added dropwise. The reaction mixture was stirred at -78°C for 1h. Usual work-up and chromatography over silica gel (hexane-Et₂O, 7%) yielded compound **10**. Hydrolysis of i-ether group and chromatography over silica gel (hexane-EtOH, 2%) furnished **11** (114 mg, 78%).

mp = 167–168°C (AcOEt). (α)_D = -37.5° (c = 0.5). IR: 3350 (bs), 3040 (w), 1670 (w), 1170 (m), 1070 (s). ¹H NMR (CDCl₃): 0.72 (3H, s, H-18), 1.02 (3H, s, H-19), 1.21 (3H, d : J = 7 Hz, H-21), 1.29 (6H, s, H-26 and H-27), 2.34 (2H, d : J = 2 Hz, H-24), 2.48 (1H, m : w_{1/2} = 20 Hz, H-20), 3.54 (1H, m : w_{1/2} = 25 Hz, H-3), 5.36 (1H, d : J = 5 Hz, H-6). ¹³C NMR in table 1. MS (50 e.V) m/e: 398 (M⁺, 10), 383 (5), 380 (4), 340 (92), 325 (11), 322 (24), 307 (14), 272 (100), 255 (44). Found: C, 81.59; H, 10.53. Calc. for C₂₇H₄₂O₂ (398.61): C, 81.35; H, 10.62.

3 β -t-Butyldimethylsilyloxy-pregn-5-en-20-one (13).

A solution of TBDMSCl (1.2 eq., 10.5 g, 68 mmol.) in dry CH₂Cl₂ (45 ml) was added to a stirred mixture of pregnenolone (**12**) (18 g, 57 mmol.) in dry (i-Pr)₂EtN (15 ml, 86 mmol.) and CH₂Cl₂/DMF (90 ml, 65/25) under Ar. The solution became homogeneous after 20 min. and a white precipitate was formed. The stirring was continued for 2.5h and then 1M aqueous K₂CO₃ (50 ml) was poured into the solution. The organic phase was separated and the aqueous phase was extracted with CH₂Cl₂. The combined extracts were dried (K₂CO₃) and evaporated to dryness. The crude product (24 g) was crystallized in CH₂Cl₂-EtOH to give pure **13** (22.2 g, 90%).

mp = 163–165°C (lit 20 162–164°C). (α)_D = +21° (c = 6). IR: 3040 (w), 1705 (s), 1250 (s), 1085 (s). ¹H NMR (CDCl₃): 0.07 (6H, s, Si(Me)₂), 0.64 (3H, s, H-18), 0.90 (9H, s, SiC(CH₃)₃), 1.01 (3H, s, H-19), 2.13 (3H, s, H-21), 3.49 (1H, m : w_{1/2} = 25 Hz, H-3), 5.34 (1H, d : J = 5 Hz, H-6). MS m/e: 430 (M⁺, 1), 415 (2), 373 (100), 355 (2), 297 (5), 281 (6). Found: C, 75.19; H, 10.79. Calc. for C₂₇H₄₆O₂Si (430.73): C, 75.28; H, 10.77.

General procedure for the reaction of protected pregnenolone (13) with 1-Alkynyllithium.

BuLi in hexane (1.3 ml, 3 mmol.) was added dropwise to a stirred and cooled solution (-78°C) of alkyne (3 mmol.) in dry THF (10 ml) under argon. After 1h, a solution of **13** (430 mg, 1 mmol.) in THF (10 ml) was introduced dropwise. The stirring was continued for further 1h at -78°C, then the dry ice bath was removed and Na₂SO₄, 10 H₂O was added. The mixture was filtered over SiO₂ and evaporated to dryness. Medium pressure chromatography over silica gel (P = 0.5 bar, Hexane-Et₂O 7.5%) gave compound **14**.

3 β -t-Butyldimethylsilyloxy-23-trimethylsilyl-24-nor-chol-5-en-22-yn-20(R)-ol (14a).

14a (492 mg, 93%) was prepared according to the general procedure as described above, using trimethylsilylacetylene (412 μ l, 3 mmol.).

mp = 124–125°C (ethanol). (α)_D = -7° (c = 1.5). IR: 3610 (m), 3460 (bm), 3040 (w), 2160 (w), 1260 (s), 1130 (m), 1090 (s). ¹H NMR (CD₂Cl₂): 0.07 (6H, s, Si(Me)₂), 0.17 (9H, s, Si(Me)₃), 0.90 (9H, s, SiC(Me)₃), 0.98 (3H, s, H-18), 1.03 (3H, s, H-19), 1.45 (3H, s, H-21), 3.50 (1H, m : w_{1/2} = 25 Hz, H-3). ¹³C NMR in table 1. MS (C.I., NH₃), m/e: 546 ((M+NH₄)⁺, 9), 528 (25), 511 (75), 488 (100), 471 (87). Found: C, 72.85; H, 10.63. Calc. for C₃₂H₅₆O₂Si₂ (528.95): C, 72.66, H, 10.67.

3 β -t-Butyldimethylsilyloxy-chol-5-en-22-yn-20(R)-ol (14b).

A solution of dichloro-1,1-propene (300 μ l, 3.15 mmol.) in dry THF (2 ml) was added dropwise to a stirred and cooled solution (-78°C) of BuLi (2.5 ml, 6 mmol.) in THF (10 ml) under Ar. After 1h at -78°C and another 1h at R.T., the reaction mixture was further cooled (-78°C) and a solution of **13** in THF (10 ml, 1 mmol.) was added dropwise. The stirring was continued for 1h at -78°C. Usual

work-up and chromatography, as described above, gave **14b** (432 mg, 92%).

mp= 142-146°C. (α)_D = -21.5° (c = 1.5). IR: 3620 (m), 3440 (bw), 3040 (w), 2260 (w), 1260 (s), 1130 (m), 1090 (s). ¹H NMR (CDCl₃): 0.06 (6H, s, Si(Me)₂), 0.90 (9H, s, SiC(Me)₃), 0.96 (3H, s, H-18), 1.01 (3H, s, H-19), 1.46 (3H, s, H-21), 1.83 (3H, s, H-24), 3.50 (1H, m: w_{1/2} = 25 Hz, H-3), 5.35 (1H, d: J = 5 Hz, H-6). ¹³C NMR in table 1. MS m/e: 470 (M⁺, 2), 455 (3), 452 (2), 413 (100), 395 (19), 373 (17), 331 (17).

3β-t-Butyldimethylsilyloxy-26,27-dinor-cholest-5-en-22-yn-20(R)-ol (14c).

14c (455mg, 94%) was prepared according to the general procedure, using a solution of 1-butyryllithium in THF (10 ml, 3 mmol.).

mp= 125-129°C. (α)_D = -17° (c = 1.8). IR: 3610 (w), 3490 (bm), 3040 (w), 2240 (w), 1255 (s), 1135 (s), 1100 (s). ¹H NMR (CDCl₃): 0.06 (6H, s, Si(Me)₂), 0.90 (9H, s, SiC(Me)₃), 0.97 (3H, s, H-18), 1.01 (3H, s, H-19), 1.12 (3H, t: J = 7.5 Hz, H-25), 1.45 (3H, s, H-21), 2.20 (2H, q: J = 7.5 Hz, H-24), 3.49 (1H, m: w_{1/2} = 25 Hz, H-3), 5.35 (1H, d: J = 5 Hz, H-6). ¹³C NMR in table 1. MS m/e: 484 (M⁺, 1), 469 (3), 466 (1), 427 (100), 409 (15), 399 (3), 373 (29), 331 (15).

3β-t-Butyldimethylsilyloxy-27-nor-cholest-5-en-22-yn-20(R)-ol (14d).

14d (460mg, 92%) was prepared according to the general procedure, using 1-pentyne (300 μl, 3 mmol.).

mp= 112-114°C (ethanol). (α)_D = -16° (c = 1.2). IR: 3620 (w), 3500 (bm), 3040 (w), 2235 (w), 1260 (m), 1140 (m), 1100 (s). ¹H NMR (CDCl₃): 0.06 (6H, s, Si(Me)₂), 0.89 (9H, s, SiC(Me)₃), 0.96 (3H, t: J = 7 Hz, H-26), 0.97 (3H, s, H-18), 1.01 (3H, s, H-19), 1.46 (3H, s, H-21), 2.17 (2H, t: J = 7 Hz, H-26), 3.51 (1H, m: w_{1/2} = 25 Hz, H-3), 5.31 (1H, d: J = 5 Hz, H-6). ¹³C NMR in table 1. MS m/e: 498 (M⁺, 2), 483 (3), 480 (4), 441 (100), 423 (19), 373 (8). Found: C, 77.23; H, 11.07. Calc. for C₃₂H₅₄O₂Si (498.85): C, 77.04; H, 10.91.

3β-t-Butyldimethylsilyloxy-cholest-5-en-22-yn-20(R)-ol (14e).

14e (493 mg, 96%) was prepared according to the general procedure, using 4-methyl-1-pentyne **32** (350 μl, 3 mmol.).

mp= 114-117°C. (α)_D = -15° (c = 2). IR: 3610 (w), 3520 (m), 3040 (w), 2230 (w), 1250 (m), 1130 (m), 1090 (s). ¹H NMR (CDCl₃): 0.06 (6H, s, Si(Me)₂), 0.89 (9H, s, SiC(Me)₃), 0.97 (6H, d: J = 6.5 Hz, H-26 and H-27), 0.98 (3H, s, H-18), 1.02 (3H, s, H-19), 1.47 (3H, s, H-21), 2.09 (2H, d: J = 6.5 Hz, H-24), 3.49 (1H, m: w_{1/2} = 25 Hz, H-3), 5.32 (1H, d: J = 5 Hz, H-6). ¹³C NMR in table 1. MS m/e: 512 (M⁺, 1), 497 (2), 494 (1), 455 (100), 437 (10), 373 (8), 331 (10).

3β-t-Butyldimethylsilyloxy-cholest-5-en-22-yn-20(R),25-diol (14f).

The carbinol **16** ²³ (450 μl, 4 mmol.) was added dropwise to a stirred and cooled mixture (-78°C) of MeLi (2.35 ml, 4 mmol, in ether) in dry THF (10 ml) under Ar. The reaction temperature was raised to -30°C during a 30 min period afterwards trimethylchlorosilane (508 μl, 4 mmol) was introduced dropwise. The stirring was continued for 1h at R.T., and the reaction was further cooled to -78°C. Another quantity of MeLi (2.30 ml, 3.91 mmol) was added dropwise, followed, after stirring for 1h, by a solution of **13** in THF (1 mmol, 10 ml). After 1h, the dry-ice bath was removed and the reaction temperature was raised to 0°C. An aqueous NH₄Cl (20 ml, 6N) was poured into the solution. The mixture was acidified to pH = 1 with HCl (1N) and then was stirred for 4h at R.T. The organic phase was separated and the aqueous phase was extracted with ether. The combined extracts were dried (Na₂SO₄) and evaporated to dryness. Medium pressure chromatography over silica gel (P= 0.2 bar, hexane-Et₂O-EtOH: 700-296-4) yielded compound **14f** (487 mg, 92%).

mp= 157-158°C (ethanol). (α)_D = -13° (c = 1.7). IR: 3380 (bs), 3040 (w), 2240 (w), 1250 (s), 1130 (s), 1100 (s). ¹H NMR (CDCl₃): 0.06 (6H, s, Si(Me)₂), 0.89 (9H, s, SiC(Me)₃), 0.98 (3H, s, H-18), 1.01 (3H, s, H-19), 1.31 (6H, s, H-26 and H-27), 1.50 (3H, s, H-21), 2.41 (2H, s, H-24), 3.49 (1H, m: w_{1/2} = 25 Hz, H-3), 5.32 (1H, d: J = 5 Hz, H-6). ¹³C NMR in table 1. MS m/e: 528 (M⁺, 1), 513 (3), 510 (2), 495 (2), 471 (100), 453 (18), 435 (3), 413 (2), 395 (5), 373 (15), 331 (14). Found: C, 74.78; H, 10.92. Calc. for C₃₃H₅₆O₃Si (528.87): C, 74.94; H, 10.67.

General procedure for the deprotection of silylether compound.

Tetrabutylammonium fluoride (Bu₄NF), (1.5 eq, 1M in THF) was added to a stirred solution of silylether **14** in dry THF (0.5 M). After 24h at R.T., Na₂SO₄, 10 H₂O was added into the solution. The mixture was filtered and evaporated to dryness. The crude compound was chromatographed over silica gel (P= 0.5 bar, hexane-Et₂O 30%) to give compound **15**.

24-Nor chol-5-en-22-yn-3β,20(R)-diol (15a).

15a (96%) was prepared according to the general procedure as described

Subst.

N°C	7a(1)	8a(1)	8b(1)	8c(1)	8d(1)	8e(1)	11(2)	15a(1)	15b(2)	15c(2)	15d(2)	15e(2)	15f(2)	13(1)	14a(1)	14b(1)	14c(1)	14d(1)	14e(2)	14f(2)	N°C
1	33.2	37.3	37.4	37.2	37.2	37.3	37.4	36.9	37.7	37.7	37.6	37.6	37.6	37.4	37.3	37.7	37.3	37.7	37.8	37.6	1
2	24.0'	31.7*	31.7*	31.6*	31.6*	31.6*	31.8*	30.7'	31.9'	32.1'	32.0'	32.0'	32.1'	31.8*	31.8*	32.2*	31.8*	32.2*	32.3*	32.2*	2
3	21.4°	71.8	71.8	71.7	71.7	71.7	71.8	70.8	71.9	72.0	71.9	71.9	71.9	72.5	72.5	72.9	72.5	73.0	73.0	72.9	3
4	13.0	42.7	42.4	42.3	42.2	42.2	42.5	41.4	42.5	42.7	43.2	42.6	42.7	42.8	42.7	43.1	42.8	43.2	43.2	43.1	4
5	35.2	140.8	140.9	140.7	140.7	140.7	141.1	140.6	141.6	141.4	141.3	141.3	141.4	141.5	141.6	142.0	141.6	142.3	142.0	141.9	5
6	82.2	121.6	121.6	121.6	121.6	121.5	121.5	120.9	121.7	121.6	121.6	121.5	121.6	120.7	120.9	121.2	120.9	121.5	121.3	121.2	6
7	34.9	31.9*	31.9*	31.8*	31.8*	31.9*	32.0*	31.4'	32.3'	32.2'	32.2'	32.1'	32.2'	32.0*	32.0*	32.4*	32.0*	32.4*	32.5*	32.4*	7
8	30.3	31.9	31.9	31.7	31.7	31.8	32.0	31.8	31.9	31.8	31.7	31.7	31.8	31.9	31.3	31.7	31.3	31.7	31.8	31.7	8
9	48.0	50.3	50.3	50.1	50.1	50.3	50.4	49.9	50.7	50.6	50.5	50.5	50.6	50.1	50.0	50.5	50.1	50.7	50.7	50.6	9
10	43.3§	36.6	36.6	36.4	36.4	36.6	36.7	36.1	37.0	36.9	36.8	36.8	36.9	36.6	36.5	36.9	36.6	36.9	37.0	36.9	10
11	22.5	21.0	21.0	20.8	20.8	20.9	21.1	20.4	21.3	21.2	21.1°	21.1	21.2	21.0	20.7	21.1	20.8	20.9	21.2	21.1	11
12	39.4	39.1	39.2	39.0	38.9	39.1	39.2	39.6	40.7	40.7	40.6	40.6	40.6	38.9	40.2	40.6	40.2	40.7	40.7	40.6	12
13	42.6§	42.4	42.3	42.2	42.2	42.2	42.5	42.9	43.6	43.5	43.5	43.4	43.5	43.9	43.2	43.5	43.1	43.5	43.6	43.5	13
14	56.1	56.5	56.6	56.4	56.4	56.5	56.6	56.0	56.9	56.8	56.7	56.7	56.7	56.9	56.2	56.7	56.3	56.8	56.9	56.7	14
15	24.8'	24.2	24.3	24.1	24.1	24.3	24.3	24.6*	24.6*	24.5*	24.5*	24.5*	24.5*	22.9	24.1	24.5	24.1	24.4	24.6	24.5	15
16	27.3	27.2	27.4	27.2	27.2	27.4	27.7	23.7*	25.5*	25.5*	25.5*	25.5*	25.6*	24.4	25.2	25.5	25.2	25.5	25.7	25.6	16
17	55.4	55.4	56.0	55.9	55.9	56.1	56.0	59.8	61.0	60.9	60.8	60.7	60.7	63.7	60.5	60.4	60.4	60.9	60.8	60.6	17
18	12.4	12.2	12.2	12.1	12.1	12.2	12.2	12.6	13.4	13.5	13.5	13.5	13.7	13.1	13.4	13.6	13.4°	13.4°	13.6	13.7	18
19	19.2	19.4	19.4	19.3	19.3	19.4	19.4	18.7	19.6	19.5	19.4	19.4	19.5	19.3	19.3	19.7	19.3	19.4	19.6	19.5	19
20	27.5	27.5	27.7	27.5	27.5	27.7	27.9	70.1	71.3	71.6	71.5	71.5	71.6	209.2	71.4	71.6	71.2	71.6	71.6	71.5	20
21	21.2°	21.4	21.7	21.7	21.7	21.8	21.7	31.0	32.8	33.0	33.1	33.2	33.3	31.3	32.5	33.0	32.8	33.1	33.3	33.2	21
22	89.3	89.3	84.1	84.3	85.1	85.9	86.4	87.3	83.6	87.1	86.0	85.3	87.4		109.7	83.4	87.0	86.0	85.5°	87.3	22
23	68.2	68.5	75.6	81.8	80.2	79.4	76.8	72.9	81.3	83.9	84.8	84.8	82.5		89.7	81.5	83.3	84.8	84.9°	82.5	23
24			3.47	12.4	20.7	28.1	34.6		3.4	12.6	20.9°	28.1	34.7			3.8	12.4	21.1'	28.2	34.7	24
25			14.4			22.5	28.4	69.9		13.9	22.4	28.3	70.2				13.7°	22.3	28.4	70.2	25
26						13.4	21.9	28.5		13.5	22.0	28.8					13.4°	22.1	28.8		26
27							21.9	28.5			22.0	28.8						22.1	28.8		27
1'	56.4														-4.6	-4.7	-4.7	-4.7	-4.5	-4.6	1'
2'														18.1	18.1	18.1	18.1	18.4	18.3		2'
3'														25.8	25.9	26.2	25.9	25.8	26.0	25.9	3'
1"															-0.3						1"

Table 1.

((1) = in CDCl₃, (2) = in CD₂Cl₂, ppm from TMS,

', °, § or * = interchangeable assignment).

Side chain carbons have chemical shifts attributed according to the incrementation method 33,34,35.

above, using $n\text{Bu}_4\text{NF}$ (3 eq) and a solution of **14a** in THF.

$\text{mp} = 215^\circ\text{--}217^\circ\text{C}$ (Ethanol). $(\alpha)_D = -41^\circ$ ($c = 1$). IR: 3640 (w), 3440 (s), 3280 (m), 3040 (w), 2120 (w), 1130 (m), 1045 (m). ^1H NMR (CDCl_3): 0.99 (3H, s, H-18), 1.03 (3H, s, H-19), 1.52 (3H, s, H-21), 2.53 (1H, s, H-23), 3.53 (1H, m : $w_1/2 = 25$ Hz, H-3), 5.36 (1H, d : $J = 5$ Hz, H-6). ^{13}C NMR in table 1. MS m/e : 342 (M^+ , 100), 327 (10), 324 (30), 273 (26), 255 (42), 241 (13). Found: C, 80.43; H, 10.27. Calc. for $\text{C}_{23}\text{H}_{34}\text{O}_2$ (342.50) : C, 80.65; H, 10.01.

Chol-5-en-22-yn-3 β ,20(R)-diol (15b).

15b (98%) was prepared according to the general procedure.

$\text{mp} = 188\text{--}190^\circ\text{C}$ (methanol). $(\alpha)_D = -33^\circ$ ($c = 1.5$). IR: 3400 (s), 3040 (w), 2260 (w), 1135 (m), 1055 (s). ^1H NMR (CDCl_3): 0.96 (3H, s, H-18), 1.02 (3H, s, H-19), 1.46 (3H, s, H-21), 1.83 (3H, s, H-24), 3.53 (1H, m : $w_1/2 = 25$ Hz, H-3), 5.36 (1H, d : $J = 5$ Hz, H-6). ^{13}C NMR in table 1. MS m/e : 356 (M^+ , 72), 341 (5), 338 (14), 323 (5), 274 (33), 256 (100), 241 (22). Found: C, 80.86; H, 10.44. Calc for $\text{C}_{24}\text{H}_{36}\text{O}_2$ (356.53) : C, 80.85; H, 10.18.

26,27-Dinor-cholest-5-en-22-yn-3 β ,20(R)-diol (15c).

15c (96%) was prepared according to the general procedure.

$\text{mp} = 135\text{--}136^\circ\text{C}$ (acetone). $(\alpha)_D = -30^\circ$ ($c = 0.8$). IR: 3440 (s), 3040 (w), 2240 (w), 1140 (m), 1045 (m). ^1H NMR (CDCl_3): 0.98 (3H, s, H-18), 1.03 (3H, s, H-19), 1.12 (3H, t : $J = 7.5$ Hz, H-25), 1.45 (3H, s, H-21), 2.20 (2H, q : $J = 7.5$ Hz, H-24), 3.53 (1H, m : $w_1/2 = 25$ Hz, H-3), 5.36 (1H, d : $J = 5$ Hz, H-6). ^{13}C NMR in table 1. MS m/e : 370 (M^+ , 29), 355 (4), 352 (7), 274 (79), 256 (100), 241 (21). Found: C, 79.11; H, 10.31. Calc for $\text{C}_{25}\text{H}_{38}\text{O}_2$, 0.5 H_2O (379.56) : C, 79.10; H, 10.36.

27-Nor-cholest-5-en-22-yn-3 β ,20(R)-diol (15d).

15d (98%) was prepared according to the general procedure.

$\text{mp} = 130\text{--}131^\circ\text{C}$ (acetone). $(\alpha)_D = -27^\circ$ ($c = 1$). IR: 3330 (s), 3040 (w), 2260 (w), 1140 (m), 1050 (m). ^1H NMR (CD_2Cl_2): 0.97 (3H, s, H-18), 0.97 (3H, t : $J = 7$ Hz, H-26), 1.02 (3H, s, H-19), 1.42 (3H, s, H-21), 2.17 (2H, t : $J = 7$ Hz, H-24), 3.50 (1H, m : $w_1/2 = 25$ Hz, H-3). ^{13}C NMR in table 1. MS m/e : 384 (M^+ , 24), 369 (4), 366 (9), 274 (67), 256 (100), 241 (25). Found: C, 79.39; H, 10.81. Calc. for $\text{C}_{26}\text{H}_{40}\text{O}_2$, 0.5 H_2O (393.59) : C, 79.34; H, 10.50.

Cholest-5-en-22-yn-3 β ,20(R)-diol (15e).

15e (98%) was prepared according to the general procedure.

$\text{mp} = 139\text{--}140^\circ\text{C}$ (acetone). $(\alpha)_D = -22^\circ$ ($c = 1.3$). IR: 3430 (s), 3040 (w), 2240 (w), 1135 (m), 1045 (m). ^1H NMR (CD_2Cl_2): 0.98 (6H, d : $J = 6.5$ Hz, H-26 and H-27), 0.99 (3H, s, H-18), 1.04 (3H, s, H-19), 1.45 (3H, s, H-21), 2.11 (2H, d : $J = 6.5$ Hz, H-24), 3.50 (1H, m : $w_1/2 = 25$ Hz, H-3). ^{13}C NMR in table 1. MS m/e : 398 (M^+ , 15), 383 (s), 380 (6), 274 (57), 256 (100), 241 (16). Found: C, 79.65; H, 10.83. Calc. for $\text{C}_{27}\text{H}_{42}\text{O}_2$, 0.5 H_2O (407.61) : C, 79.55; H, 10.63.

Cholest-5-en-22-yn-3 β ,20(R),25-triol (15f).

15f (96%) was prepared according to the general procedure. Chromatography

($P = 0.15$ bar; hexane-ether-ethanol : 50-47-3) gave the pure compound. $\text{mp} = 220\text{--}221^\circ\text{C}$ (AcOEt). $(\alpha)_D = -23^\circ$ ($c = 0.8$) IR: 3420 (s), 3040 (w), 2260 (w), 1135 (m), 1060 (m). ^1H NMR (CD_2Cl_2): 1.00 (3H, s, H-18), 1.04 (3H, s, H-19), 1.29 (6H, s, H-26 and H-27), 1.49 (3H, s, H-21), 2.40 (2H, s, H-24), 3.49 (1H, m : $w_1/2 = 25$ Hz, H-3). ^{13}C NMR in table 1. MS m/e : 414 (M^+ , 13), 399 (1), 396 (6), 381 (5), 338 (13), 274 (45), 256 (100), 241 (14). Found: C, 78.23; H, 10.36. Calc. for $\text{C}_{27}\text{H}_{42}\text{O}_3$ (414.61) : C, 78.21; H, 10.21.

Acknowledgments.

The authors wish to thank Mrs Elisabeth Krempf for NMR spectra, Dr Gerard Teller and Raymond Huebert for mass spectra and Mrs Michèle François for microanalysis. We express our gratitude to Pr G. Ourisson and Pr J.A. Hoffmann for valuable discussions and for critical reading of this manuscript.

REFERENCES.

- 1) M. Lagueux, J.A. Hoffmann, P. Goltzené, C. Kappler, G. Tsoupras, C. Hetru and B. Luu, "Biosynthesis, Metabolism and Mode of Action of Invertebrate Hormones", (edited by J.A. Hoffmann and M. Porchet), Springer-Verlag, Berlin-Heidelberg, (1984).

- 2) J.A. Hoffmann and M. Lagueux, "Comprehensive Insect Physiology, Biochemistry and Pharmacology", (edited by G.A. Kerkut and L.I. Gilbert), Pergamon Press, Oxford-New-York, 1, (1985).
- 3) J.A. Hoffmann, Insect Biochem., 16, 1-9, (1985).
- 4) C. Walsh, Tetrahedron, 38, 871-909, (1982).
- 5) R.H. Abeles, Chem. Eng. News, 61, 48-56, (1983).
- 6) C. Walsh, Annu. Rev. Biochem., 53, 493-535, (1984).
- 7) C. Hetru, C. Kappler, J.A. Hoffmann, R. Nearn, B. Luu and D.H.S. Horn, Mol. Cell. Endocrinol., 26, 51-80, (1982).
- 8) T. Haag, M.F. Meister, C. Hetru, C. Kappler, Y. Nakatani, J.P. Beaucourt, B. Rousseau and B. Luu, Insect Biochem., 17, 291-301, (1987).
- 9) C. Kappler, private communication.
- 10) P.R. Ortiz de Montellano and M.A. Correia, Annu. Rev. Pharmacol. Toxicol., 23, 481-503, (1983).
- 11) A. Nagahisa, R.W. Spencer and W.H. Orme-Johnson, J. Biol. Chem., 258, 6721-6723, (1983).
- 12) D.M. Piatak and J. Wicha, Chem. Rev., 78, 200-241, (1978).
- 13) J. Redpath and F.J. Zeelen, Chem. Soc. Rev., 12, 75-98, (1983).
- 14) W.G. Salmond, M.C. Sobala and K.D. Maisto, Tetrahedron Lett., 1237-1238, (1977).
- 15) H. Normant, Angew. Chem., 79, 1029-1076, (1967).
- 16) M. Schwarz and R.M. Waters, Synthesis, 567-568, (1972).
- 17) D.N. Brattesani and C.H. Heathcock, Syn. Commun., 3, 245-248, (1973).
- 18) C. Huynh and G. Linstrumelle, J. Chem. Soc. Chem. Commun., 1133-1134, (1983).
- 19) E. Zadok and Y. Mazur, J. Org. Chem., 47, 2225-2227, (1982).
- 20) J.H. Dygos and B.N. Desai, J. Org. Chem., 44, 1590-1596, (1979).
- 21) L. Lombardo, Tetrahedron Lett., 25, 227-228, (1984).
- 22) T. Hiyama, M. Shinoda and H. Nozaki, J. Am. Chem. Soc., 101, 1599-1600, (1979).
- 23) P. Luger, M. Prost and R. Charlier, Helv. Chim. Acta, 42, 2379-2393, (1959).
- 24) M. Lagueux and J.A. Hoffmann, J. Insect Physiol., 23, 109-120, (1977).
- 25) A. Burger, J.P. Roussel, F. Colobert, C. Hetru, B. Luu and J.A. Hoffmann, Pest. Biochem. Physiol. in press.
- 26) T. Haag, C. Hetru, C. Kappler, B. Rousseau, B. Luu and J.A. Hoffmann, submitted to Tetrahedron.
- 27) D.H.S. Horn and R. Bergamasco, "Comprehensive Insect, Physiology, Biochemistry and Pharmacology", (edited by G.A. Kerkut and L.I. Gilbert), Pergamon Press, Oxford-New-York, 1, 232, (1985).
- 28) G.D. Prestwich and S. Phirwa, Tetrahedron Lett., 24, 2461-2464, (1983).
- 29) T.B. Kline and G.D. Prestwich, Tetrahedron Lett., 23, 3043-3046, (1982).
- 30) M. Morisaki, N. Awata, Y. Fujimoto and N. Ikekawa, J. Chem. Soc. Chem. Commun., 362-363, (1975).
- 31) M.F. Costet, M.E. Achouri, M. Charlet, R. Lanot, P. Benveniste and J.A. Hoffmann, Proc. Natl. Acad. USA, 84, 643-647, (1987).
- 32) L. Brandsma, "Preparative Acetylenic Chemistry", Elsevier, Amsterdam-London-New-York, 187 and 111, (1971).
- 33) J.E. Dubois and J.P. Doucet, J. Chem. Res. (S), 82-83 and 84-85, (1980).
- 34) J.E. Dubois and J.P. Doucet, Org. Magn. Reson., 11, 87-96, (1978).
- 35) A.G. Proidakov, B.I. Istomin, G.A. Kalabin, V.I. Donskikh and V.M. Polonov, Org. React. (Tartu), 16, 539-569, (1979).